Lymphoma treatment response monitoring with genetic testing

This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.

This study is looking at people with peripheral T-cell lymphoma, a type of blood cancer. It will use genetic testing to understand different subtypes of the cancer and how they affect patients' outcomes.

This trial looks at your tumor’s genetic information from stored tissue to help match you to early-phase treatment options. It may help doctors find a therapy that fits your tumor, especially when standard options have limited benefit.

This study follows people with newly diagnosed non-Hodgkin lymphoma to collect information about how they respond to treatment. It aims to improve understanding and care for this type of blood cancer.

This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.

This study uses a blood test to detect cancer DNA (ctDNA) in children and young adults with classical Hodgkin lymphoma. The goal is to see if this non-invasive test can help track how well treatment is working.